r/CABAinvest

So Happy I did, finally some green. I know we might see red again but these days are worth it. Let’s gooo

$CABA presented very encouraging rese-cel results in myasthenia gravis at the AANEM Annual Meeting, Sept. 29 on Oct. 2.

The headline: 10 of 13 hard-to-treat MG patients had meaningful improvement after ONE infusion of rese-cel while OFF their non-steroid immunomodulatory drugs. Nine of those 10 were also off steroids or tapering them. Chemotherapy preconditioning was administered prior to rese-cel.

The improvement was substantial. Among patients who had not required rescue treatment and had reached each follow-up point, average MG-ADL scores improved 7.4 points at 12 weeks (n=11) and 9.8 points at 24 weeks (n=4). The smaller n=4 simply reflects how many patients had reached 24 weeks with data available at the cutoff.

Safety also looked encouraging as only 2 of 13 had CRS, both low-grade, and no ICANS was reported. Very different safety profile than the 2 big pharma CAR-at trials that were paused.

Still a small early-stage study, but 10 of 13 refractory MG patients improving while off their immunomodulatory drugs after a single infusion is a very encouraging signal for rese-cel.

For investors, the key catalyst now is more patients plus longer follow up. If these results hold up, the $CABA stock price should rocket.

To me anyway, nothing has changed with the upward trajectory of the company and rese-cel and the current share price is a bargain - at or near the 52 week low and an opportunity to add shares cheaply.

NeurologyLive:
https://www.neurologylive.com/view/single-infusion-rese-cel-yields-meaningful-responses-off-immunomodulators-phase-1-2-reset-mg-trial